Press Release

At AbilityPharma we are very pleased to announce the start of a crowdfunding campaign through de Capital Cell

August 24, 2018

At AbilityPharma we are very pleased to announce the start of a crowdfunding campaign through de Capital Cell. This campaign with the slogan #nosinti will open to the public on September 12, even so we have already achieved 54.3% of our final goal.

 
 
We have been studying a specific drug, called ABTL0812, for several years. It induces cancer cell death through autophagy (self-digestion).

ABTL0812 is currently in phase 2 clinical trials to treat endometrial cancer and lung cancer in 80 patients in centers in Spain and France. In addition, as we announced a few months ago, the FDA (Food and Drug Administration of the United States) has approved a phase 1/2a clinical trial with ABTL0812 in combination with gemcitabine and nab-paclitaxel in patients with advanced metastatic cancer of the pancreas as first line therapy and as maintenance after chemotherapy.




 
The main objective with our crowdfunding campaign is to raise 1 million euros in order to finish the phase 1/2 study with the development of additional biomarkers and the development of a new formulation.

Why investing in this company?

This is a unique opportunity to invest in a company at a very advanced stage of development. Although the scientific risk still exists, we have managed to reduce it with the success of the first trial with patients, with positive results.
 
A successful outcome of the second trial would put us in a position of strength in the negotiations of a licensing agreement of the drug with a pharmaceutical company or would allow us to go public in a stock market. In both cases, investors could achieve a very high profitability. The total financing round is of 5 million euros and we are in very advanced negotiation swith several specialized investment funds.

Would you like to know more about our project? Do not hesitate to send us an email to the following address: contact@abilitypharma.com

 

LATEST NEWS

05.11.2020

Press Release

AbilityPharma receives the approval from the FDA and the AEMPS to start the clinical trial of its molecule against pancreatic cancer in the US and Spain + info
22.10.2020

Press Release

AbilityPharma receives a 1.6 million euro grant from the FDA and opens a crowdfunding campaign in Capital Cell + info
22.09.2020

Press Release

ABILITYPHARMA PRESENTS THE RESULTS OF A NEW FIRST-LINE TREATMENT FOR ENDOMETRIAL CANCER + info
09.06.2020

Press Release

AbilityPharma publishes full characterization of mechanism of action of ABTL0812, a Phase II clinical inducer of cytotoxic autophagy in cancer cells, in Autophagy journal + info
25.03.2020

Press Release

AbilityPharma awarded €5 million from the Horizon Europe EIC Accelerator Pilot Program to conduct a Phase 2b clinical trial with ABTL0812 in patients with advanced pancreatic cancer + info
12.09.2019

Press Release

AbilityPharma rises € 3.5 million in a financing round to complete the current oncologic phase 2 clinical trial and license ABTL0812 to an international pharmaceutical company + info
31.05.2019

Press Release

Ability Pharmaceuticals Announces the Presentation of the First Results of ABTL0812 as First Line in Patients with Endometrial or Lung Cancer at 2019 ASCO Annual Meeting + info
04.02.2019

Press Release

Ability Pharmaceuticals Announces the Approval in China of a Clinical Study in Pancreatic Cancer with ABTL0812 + info
30.01.2019

Press Release

Ability Pharmaceuticals is attending the BIOMED EVENT® by INVEST SECURITIES and the Cholangiocarcinoma Foundation Annual Conference + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG